News Releases | Investor Relations - Sangamo Therapeutics, Inc.
Nov 12, 2024 · Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases Aug 06, 2024
Sangamo Therapeutics, Inc. (SGMO) Latest Stock News
Get the latest Sangamo Therapeutics, Inc. (SGMO) stock news and headlines to help you in your trading and investing decisions.
Sangamo Therapeutics to Regain Full Rights to Hemophilia A …
Dec 30, 2024 · RICHMOND, Calif.--(BUSINESS WIRE)--Dec. 30, 2024-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced it will regain development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for the treatment of adults with moderately severe to severe ...
Sangamo slashes time to market for Fabry gene therapy as FDA …
Oct 22, 2024 · Sangamo Therapeutics has identified a shortcut to market for its Fabry disease candidate, aligning with the FDA on a pathway that could slash three years from the time to market and free it...
Sangamo Therapeutics Stock Plunges As Pfizer Terminates …
Dec 31, 2024 · On Monday, Sangamo Therapeutics, Inc. (NASDAQ: SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for...
Sangamo Therapeutics to Regain Full Rights to Hemophilia A …
RICHMOND, Calif., December 30, 2024 -- (BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced it will regain development and commercialization...
Sangamo Therapeutics and Astellas Announce Capsid License …
Dec 19, 2024 · About Sangamo Therapeutics. Sangamo Therapeutics is a genomic medicine company dedicated to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases who do not have adequate or any treatment options. Sangamo believes that its zinc finger epigenetic ...
Sangamo Therapeutics Stock Crashes as Pfizer Ends
Dec 31, 2024 · Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement. The two drugmakers were working on a treatment for hemophilia in adults.
Pfizer Ends Sangamo Alliance With Gene Therapy for Hemophilia …
Dec 31, 2024 · Pfizer is walking away from partner Sangamo Therapeutics ahead of expected regulatory submissions for the hemophilia A gene therapy they co-developed. Cash-strapped Sangamo said it is now...
Astellas pays Sangamo $20M to boost neurological gene therapies
Dec 19, 2024 · Astellas is continuing to strengthen its neurological disease gene therapy capabilities, handing Sangamo Therapeutics $20 million upfront to help bypass the blood-brain barrier (BBB).
- Some results have been removed